| Literature DB >> 34479546 |
Xiaoxuan Ling1, Yali Han1, Jinxue Meng1, Bohuan Zhong1, Jialong Chen1,2, He Zhang1,2, Jiheng Qin1, Jing Pang1, Linhua Liu3,4.
Abstract
Extrachromosomal circular DNA (eccDNA) refers to a type of circular DNA that originate from but are likely independent of chromosomes. Due to technological advancements, eccDNAs have recently emerged as multifunctional molecules with numerous characteristics. The unique topological structure and genetic characteristics of eccDNAs shed new light on the monitoring, early diagnosis, treatment, and prediction of cancer. EccDNAs are commonly observed in both normal and cancer cells and function via different mechanisms in the stress response to exogenous and endogenous stimuli, aging, and carcinogenesis and in drug resistance during cancer treatment. The structural diversity of eccDNAs contributes to the function and numerical diversity of eccDNAs and thereby endows eccDNAs with powerful roles in evolution and in cancer initiation and progression by driving genetic plasticity and heterogeneity from extrachromosomal sites, which has been an ignored function in evolution in recent decades. EccDNAs show great potential in cancer, and we summarize the features, biogenesis, evaluated functions, functional mechanisms, related methods, and clinical utility of eccDNAs with a focus on their role in evolution and cancer.Entities:
Keywords: Cancer; Evolution; Extrachromosomal circular DNA; Function of eccDNA
Mesh:
Substances:
Year: 2021 PMID: 34479546 PMCID: PMC8414719 DOI: 10.1186/s12943-021-01413-8
Source DB: PubMed Journal: Mol Cancer ISSN: 1476-4598 Impact factor: 27.401
Fig. 1Origins and types of eccDNA. A EccDNA is enriched in specific areas (hotspots), including untranslated (3’-UTR and 5’-UTR) areas, regions with a high GC content, and transcriptionally active chromatin. B EccDNA types based on the genetic content [34]
Fig. 2Mechanisms of eccDNA biogenesis. A A dicentric anaphase bridge forms due to the loss of telomeres, and the telomere-free bridge is elongated by a repetitive cycle of replication, broken into random fragments under stress, and looped out to form eccDNA. B Chromothripsis, a type of severe DNA damage caused by exogenous stress, forms single- or double-strand breakages. With the DNA repair system, most of the DNA fragments are removed by different mechanisms, but some of the fragments are ligated and circularized into eccDNAs. C The translocation-deletion-amplification mechanism, which is frequently triggered by exogenous stimuli, is repaired or removed by the DNA repair system, but the retained or cleaved DNA fragments may generate eccDNAs. D Circular DNAs are generated during the DNA synthesis process in a DNA slippage and R-loop manner. Circular DNAs are produced by cleavage and ligation and can be enlarged by the integration of other DNA components, such as TEs and enhancers/promoters. BFB, breakage-fusion-bridge
Fig. 3Identified functions of eccDNA. Increasing studies have implied the great promise of eccDNA in cancer research because the identified functions work synergistically in cancer initiation and progression
Fig. 4Diversity of eccDNA and its roles in evolution. A Structural diversity of eccDNA. Different types of eccDNA have different genetic contents, which constitute the eccDNA structural diversity. B Functional diversity of eccDNA. The eccDNA structural diversity and unique topological structure contribute to the multiple functions of eccDNA by potentially driving the expression of coding RNAs, noncoding RNAs, and other RNAs. C Numerical diversity of eccDNA as well as the role and mechanism of eccDNA in evolution (modified based on Verhaak et al. [71]). Cells with eccDNA functional diversity formed from different pathways triggered by exogenous stimuli have an enhanced opportunity to generate eccDNA numerical diversity, which is attributed to cell survival advantages in environmental adaptation and evolution. The cycle number represents the copy number of eccDNA
Summary of functions of eccDNAs related to cancer
| Type of cancer | Genes | Drugs/Treatment | Biogenesis | Function | References |
|---|---|---|---|---|---|
| Pancancer (17 different cancer types) | EGFR | Erlotinib | Rearrangement | Contributes to intratumoral heterogeneity via the reintegration of EGFRvIII-containing eccDNA elements and by promoting the transcription of EGFR; additional rearrangements and heterogeneity after erlotinib withdrawal. | [ |
| Pancancer (17 different cancer types) | MYC | NA | Rearrangement | Contributes to intratumoral heterogeneity by promoting the transcription of MYC. | [ |
| Pancancer (prostate cancer, colon cancer, glioblastoma) | EGFR, MYC, CDK4 and MDM2 | NA | NA | Promotes the expression of oncogenes (EGFR, MYC, CDK4, and MDM2) encoded on eccDNA by influencing the chromatin organization. | [ |
| Glioblastoma | EGFR | Irradiation | NA | Cells with amplified EGFR on eccDNA exhibit stronger invasive properties and radiation resistance. | [ |
| Glioblastoma | MET | Capmatinib | NA | Amplified MET on eccDNA drives early tumor formation, and the elimination of eccDNA increases the survival benefit. | [ |
| Glioblastoma | MYC | NA | NA | EccDNA harboring MYC amplification contributes to recurrent tumors. | [ |
| Glioblastoma | EGFR | Dacomitinib | NA | EccDNA harboring EGFRvIII mutation amplification drives recurrent tumors upon treatment with dacomitinib. | [ |
| Glioblastoma | EGFRvIII | Temozolomide with adjuvant radiation | NA | EccDNA containing EGFRvIII provides cells with growth advantages. | [ |
| Glioblastoma | MDM2 | Erlotinib | NA | The amplification of MDM2 on eccDNA promotes erlotinib resistance. | [ |
| Neuroblastoma | MYCN | NA | Involves neo-topologically associated domains | The hijacking of enhancers and insulators drives the expression of MYC on eccDNA. | [ |
| Neuroblastoma | MYCN | NA | DNA repair or replication-associated mechanisms | Drives oncogenic genome remodeling and the expression of oncogenes. | [ |
| Neuroblastoma | MYCN | Hydroxyurea | NA | The elimination of amplified MYCN on eccDNAs increases the sensitivity to hydroxyurea. | [ |
| Cervical cancer | DHFR | Methotrexate | Chromothripsis, BFB | Adaptation to increased selection pressure is induced by methotrexate by increasing the DHFR gene copies in eccDNA, which promotes DHFR expression. | [ |
| Cervical cancer | DHFR | Methotrexate | BFB | The amplification of DHFR located on eccDNA promotes resistance to methotrexate. | [ |
| Breast Cancer | DHFR | Methotrexate | NA | Irradiation induces methotrexate resistance due to eccDNA with amplified DHFR. | [ |
| Oral squamous cell carcinoma | MDR1 | Hydroxyurea | NA | Loss of MDR1-carrying eccDNA induced by hydroxyurea increases drug sensitivity. | [ |
| Colon cancer | DHFR | Methotrexate | NA | The elimination of DHFR-containing eccDNA promotes sensitivity to methotrexate and inhibits proliferation. | [ |
| Colorectal cancer | Not define | NA | Chromothripsis, a process of multistep evolution that drives eccDNA formation | eccDNA may drive cancer progression. | [ |
| Leukemia | MYC | Hydroxyurea | NA | Hydroxyurea inhibits tumorigenicity by eliminating amplified MYC on eccDNAs. | [ |
| Leukemia | c-Myc | Hydroxyurea and retinoic acid | NA | Hydroxyurea inhibits tumorigenicity by eliminating c-Myc-bearing eccDNAs. | [ |
| Undefined | microRNA | NA | NA | Expresses functional small regulatory RNA. | [ |
NA Not available
Overview of methods for eccDNA investigation
| Methods | Description | Advantage or Limitation | References |
|---|---|---|---|
| Electron microscopy | Localization, identification, quantification | No sequence information | [ |
| Karyotype | Localization, identification, quantification | No sequence information | [ |
| 2D gel electrophoresis | Identification | No sequence information | [ |
| Southern blotting | Quantification | Little sequence information | [ |
| Inverse PCR | Quantification, identification | Little but useful sequence information | [ |
| FISH | Localization, identification, quantification | Little sequence information | [ |
| Density gradient centrifugation | Isolation and purification | Laborious | [ |
| Methods based on next-generation sequencing | Localization, quantification, high resolution, (1) tagmentation method is more sensitive than (2) nuclease digestion (Msp); (3) exonuclease III digestion; (4) exonuclease V digestion; (5) rolling-amplification | High throughput, high resolution, sensitive, expensive | [ |
Fig. 5Flowchart for eccDNA research. The schematic comprehensively details eccDNA research, and some of the steps are not essential. In their research, researchers can select some of the steps based on the strengths and limitations of the methods listed in Table 1. Karyotyping and EMs, which are classic techniques in most labs, can qualitatively identify eccDNAs. Deep sequencing shows numerous strengths but is expensive. The process of eccDNA structure validation, which can be achieved by an integrated approach combining FISH and inverse PCR, is critical for studying eccDNA. Functional and mechanistic assays include transcriptomic, proteomic, and other approaches
Summary of the clinical utility of eccDNA
| Clinical utility | Type of cancer | References |
|---|---|---|
| • Modulates the copies of oncogene-harboring eccDNAs to improve the efficacy of cancer treatment. | ||
| (I) The elimination of eccDNAs carrying oncogenes promotes drug sensitivity. | Neuroblastoma | [ |
| (II) Chemotherapeutic drugs promote the elimination of eccDNA containing amplified genes. | Neuroblastoma, colon cancer | [ |
| (III) DNA-PKs or PARP inhibitors decrease drug resistance and eccDNA production. | Colorectal cancer | [ |
| • EccDNAs serve as promising biomarkers for cancer monitoring and prognosis. | ||
| (I) Normal and cancerous tissues release eccDNAs into the circulation, which suggests promising potential for liquid biopsy. | Ovarian cancer, lung cancer | [ |
| (II) Patients with eccDNA carrying amplified MYCN exhibit worse overall survival than patients with MYCN-amplified tumors lacking such rearrangements. | Neuroblastoma | [ |
| (III) EccDNA in the circulation is sharply decreased after surgery in patients with cancer. | Ovarian cancer, lung cancer | [ |
| (IV) EccDNA is responsible for tumor recurrence. | Glioblastoma multiforme | [ |
| • EccDNA serves as a promising tool for tracing the origin of the primary cancer. | ||
| (I) The presence of eccDNA in the circulation is helpful for discriminating the origin of primary cancer. | NA | [ |
| (II) The methylation status of eccDNA in the circulation is different and unique under specific physiological conditions, which makes eccDNA a trace biomarker. | Not applicable | [ |
NA Not available